Gestational Diabetes is diabetes first recognised during pregnancy, most commonly identified through screening or diagnostic testing in the second or third trimester. Pregnancy naturally produces hormonal changes that increase insulin resistance, allowing more glucose to remain available to support fetal growth. Normally, the pancreas compensates by producing additional insulin, but when insulin production cannot adequately overcome pregnancy-related insulin resistance, blood glucose rises.
Gestational diabetes is therefore primarily a disorder of glucose regulation in pregnancy rather than simply the result of eating sugar. It differs from pre-existing type 1 or type 2 diabetes, although diabetes that was present before conception may occasionally be diagnosed for the first time during pregnancy. Diagnostic thresholds vary somewhat between international organisations and healthcare systems, so terminology and testing pathways must be interpreted in their local context. Gestational diabetes usually improves after delivery because placental hormones fall rapidly, but it is an important marker of increased future risk of type 2 diabetes and therefore has implications beyond pregnancy itself.
Risk factors for Gestational Diabetes include previous gestational diabetes, higher maternal body weight, a previous large-for-gestational-age baby, a family history of type 2 diabetes, certain ethnic backgrounds with higher population-level diabetes risk, polycystic ovary syndrome and increasing maternal age. It can also occur in people without recognised risk factors, which is why some healthcare systems use universal screening while others use risk-based testing.
The physiological basis involves placental hormones and inflammatory and metabolic changes that progressively reduce insulin sensitivity as pregnancy advances. Human placental lactogen, progesterone, cortisol and other hormones contribute to this metabolic adaptation. Genetic susceptibility and pre-pregnancy insulin sensitivity influence how effectively the pancreas responds. Gestational diabetes should therefore not be understood as a simple failure of dietary discipline. Diet, physical activity and body composition influence glucose regulation, but the condition results from interaction between pregnancy physiology and individual metabolic capacity.
Gestational Diabetes may cause no noticeable symptoms, which is why screening is important. When symptoms do occur, they can include increased thirst, increased urination, fatigue and blurred vision, although these are nonspecific and can also occur in normal pregnancy or other conditions. The principal clinical concern is that sustained maternal hyperglycaemia exposes the fetus to increased glucose. Glucose crosses the placenta, while maternal insulin does not cross in the same way, so the fetus responds by producing more insulin.
Fetal hyperinsulinaemia promotes growth and can result in a larger baby, particularly increased fat deposition. This can increase the likelihood of shoulder dystocia and birth trauma. Maternal hyperglycaemia can also contribute to excessive amniotic fluid, hypertensive disorders and increased likelihood of operative delivery. Poorly controlled diabetes that predates pregnancy carries additional risks, including congenital abnormalities, but gestational diabetes generally develops after organ formation and therefore has a different risk profile.
Diagnosis commonly uses an oral glucose tolerance test in which blood glucose is measured after fasting and then after a specified glucose drink. The exact timing, glucose concentration and diagnostic thresholds depend on the guideline system being followed. Screening is often performed around 24 to 28 weeks because insulin resistance increases substantially during this period, although earlier testing may be offered to people at higher risk.
A diagnosis should be distinguished from an isolated raised glucose measurement because diagnostic criteria are based on specified thresholds and testing conditions. Once diagnosed, monitoring may involve capillary blood-glucose measurements at fasting and after meals. Targets are set by the treating maternity or diabetes team and can differ between guidelines. Assessment may also include fetal growth surveillance, particularly when glucose control is suboptimal or other risk factors are present. The purpose of diagnosis is not simply to label the condition but to identify pregnancies in which glucose management can reduce maternal and fetal complications.
Initial management generally focuses on dietary modification, appropriate physical activity and structured glucose monitoring. A balanced eating pattern can reduce large post-meal glucose excursions without requiring complete avoidance of carbohydrate. Distribution of carbohydrate across meals and snacks, choosing higher-fibre sources and avoiding excessive intake of rapidly absorbed sugars can be useful. Physical activity after meals may improve insulin sensitivity when medically appropriate. If glucose targets are not achieved despite lifestyle measures, medication may be required.
Insulin has a long-established role in pregnancy because it does not cross the placenta in clinically significant amounts and can be titrated according to glucose patterns. Metformin is also used in some healthcare systems and circumstances, although practice varies because clinicians consider placental transfer, maternal preferences, gestational timing and local guidance. Treatment is adjusted according to actual glucose measurements rather than symptoms alone.
The main fetal consequence of poorly controlled Gestational Diabetes is excessive growth, but other complications can occur. Newborns may experience hypoglycaemia after birth because their insulin production remains elevated while the maternal glucose supply is suddenly interrupted. They may also have respiratory difficulties, jaundice or other neonatal problems, particularly when diabetes is poorly controlled or coexists with other complications. Maternal risks include pre-eclampsia, induction of labour and caesarean birth.
The absolute risk for an individual depends on glucose control, gestational age, fetal growth, maternal characteristics and associated conditions. Delivery planning is therefore individualised rather than automatically requiring early delivery or caesarean section. After birth, insulin resistance generally falls quickly and glucose levels often return to normal, but follow-up testing is important because gestational diabetes identifies a substantially increased lifetime risk of developing type 2 diabetes. Lifestyle measures and periodic diabetes screening can therefore have long-term preventive value.
Gestational Diabetes is sometimes incorrectly portrayed as either harmless or entirely caused by diet. Both interpretations are misleading. Mild, well-controlled gestational diabetes can be managed successfully, but untreated or poorly controlled hyperglycaemia is associated with clinically important risks. Conversely, a diagnosis does not mean that complications are inevitable, and treatment can substantially improve the metabolic environment. The condition also does not necessarily imply permanent diabetes; most people have normal glucose regulation after pregnancy, although their future risk remains elevated.
Another distinction is between gestational diabetes and overt diabetes first detected during pregnancy. If glucose levels are sufficiently high to meet criteria for diabetes outside pregnancy, clinicians may classify the condition differently because it can indicate previously unrecognised type 2 diabetes. These distinctions affect follow-up, treatment intensity and counselling.
Gestational Diabetes has broader significance because pregnancy can reveal an underlying tendency towards insulin resistance and future metabolic disease. Postpartum glucose testing is therefore recommended according to local clinical guidance, followed by periodic assessment because recurrence in subsequent pregnancies is common and later type 2 diabetes is more likely. Future pregnancies may involve earlier screening and closer monitoring. The condition also illustrates the interaction between placental biology, maternal metabolism and fetal growth.
Research continues to examine how diagnostic thresholds, treatment strategies and continuous glucose monitoring affect outcomes, particularly because very mild hyperglycaemia can create difficult questions about how much treatment is beneficial. Clinically, the essential principle is that management aims to maintain glucose within pregnancy-specific targets while avoiding unnecessary treatment burden and hypoglycaemia. Gestational Diabetes is consequently both a pregnancy-specific metabolic disorder and a long-term marker of cardiometabolic risk.
